Practical considerations for optimising homologous recombination repair mutation testing in patients with metastatic prostate cancer

Analysis of the genomic landscape of prostate cancer has identified different molecular subgroups with relevance for novel or existing targeted therapies. The recent approvals of the poly(ADP‐ribose) polymerase (PARP) inhibitors olaparib and rucaparib in the metastatic castration‐resistant prostate...

Descripción completa

Detalles Bibliográficos
Autores principales: Gonzalez, David, Mateo, Joaquin, Stenzinger, Albrecht, Rojo, Federico, Shiller, Michelle, Wyatt, Alexander W, Penault‐Llorca, Frédérique, Gomella, Leonard G, Eeles, Ros, Bjartell, Anders
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8185363/
https://www.ncbi.nlm.nih.gov/pubmed/33630412
http://dx.doi.org/10.1002/cjp2.203

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8185363/
https://www.ncbi.nlm.nih.gov/pubmed/33630412
http://dx.doi.org/10.1002/cjp2.203

Ejemplares similares